BeiGene's late stage trial shows promising numbers; Amgen to study sotorasib dosage after FDA recommendation
Big Chinese pharma player BeiGene $BGNE is showing off some promising numbers from its interim analysis of a late-stage, head-to-head trial pitting their BTK drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
